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for the HIV-1 proteins p17 and p24, for which we have previously computed fitness landscapes and validated in extensive comparisons against experimental and clinical data to demonstrate that they are not contaminated with signatures of adaptive immune pressure [1, 2] . In sum, our targeting frequency estimate for NS5B, prior empirical, numerical, and theoretical studies [2] , and direct comparisons against clinical data and experimental measurements described in the main text, all provide support that our inferred NS5B fitness landscape does not contain footprints of adaptive immunity.
II. MODEL AUGMENTATION
The Potts model fitted to the MSA data detailed in the main text contained parameters describing the fitness impact of each amino acid residue in each single position, and each pair of amino acids in each pair of positions. In comparing our model predictions against clinical and experimental data, we twice encountered a situation in which the experimentally reported viral strains contained amino acid residues absent in our MSA and therefore not contained within our model. Rather than simply discarding these sequences from our comparisons, we constructed two separate augmented models containing parameters for amino acid variants that were unobserved in the MSA.
The first augmentation was required in order to fully compare our model predictions with the measured in vitro fitness data in Section 3.1. Of the 31 in vitro measurements we collated from the literature, 30 of them -all from the same lab [10, 11] -used the H77 sequence (GenBank Accession No. M67463) as their wild type baseline sequence, rather than the more commonly used H77S.3 sequence (GenBank Accession No. AF011751). Our fitted Potts model contained all amino acids in H77S.3, but did not contain parameters for six residues in H77: K2469, A2512, L2637, R2703, R2715, and W2925. To assign energies to all strains considered, we augmented our model with parameters for these six unobserved residues to generate Augmented Model I.
The second augmentation was required to assign energies to all of the clinically observed escape, and compensatory, mutations that we analyzed in Section 3.2, and the sequences in the longitudinal studies considered in Section 3.4. The sequences from the longitudinal studies contained 456 residues in particular positions not observed in our MSA. The clinical escape mutations contained two amino acids that were not contained in our MSA, and which were coincident with two of the 456 unobserved amino acids within the longitudinal data. Accordingly, in order to assign energies to all longitudinal strains and escape mutations we augmented our model with parameters for the 456 unobserved residues to generate Augmented Model II.
To perform model augmentation it is necessary to incorporate h i and J ij parameters for each unobserved residue in position i. To estimate values of these model parameters, we specified the probability with which the unobserved amino acids appear within the MSA to be non-zero using pseudo-counts [12, 13] . This procedure adds a (possibly non-integer) number of fictitious observations of the amino acid within the MSA to reflect the belief that the probability of observing this amino acid in this position is not precisely zero, but rather a low-probability event that is not observed within the finite number of strains within the MSA. From a Bayesian perspective, the use of pseudo-counts may be considered the incorporation of prior knowledge into the model inference procedure [12] , in this case the prior knowledge that the probability that these amino acids exist within an HCV strain should be non-zero. In this work, we specify the pseudo-count modified probability of observing amino acid A in position i, P i (A), as,
where N is the number of sequences in our MSA, q i is the number of distinct amino acids (including this unobserved amino acids added to the model) at position i, z k i is the identity of the amino acid in position i in sequence k of the MSA, δ A,z k i is an indicator function that is unity when A = z k i and zero otherwise, and λ is a pseudo-count [13, 14] . At positions where we supplement our model with unobserved amino acids, we choose λ = q i N N +1−q i such that for an unobserved amino acid A at that position, P i (A) = 1 N +1 . This quantity may be interpreted as an estimated upper bound on the frequency with which amino acid A is observed in position i corresponding to supplementing the MSA with one (hypothetical) additional sequence containing amino acid A in position i. We then iteratively rescaled the two-position target probabilities, P ij (A, B), such that the marginal probabilities over i and j are consistent with the one-position target probabilities, P i (A) [1] . At positions where no unobserved amino acids were added, no pseudo-counts were added (i.e., λ = 0).
Having specified the pseudo-count modified probabilities, we re-fitted the parameters of the Potts model using the procedure detailed in Section 2.2. Constituting a relatively small perturbation to the target probabilities for the fitting procedure, the model parameters changed very little from their unaugmented values, and by initializing the {h i } and {J ij } parameters to their unaugmented values, the fitting procedure quickly converged. The energy predictions of the augmented and unaugmented models are in close agreement, as illustrated by the correspondence of strain energies in Figure 2 (augmented model) and Figure S3 (unaugmented model).
III. PREDICTED FITNESS COSTS OF CLINICAL ESCAPE MUTATIONS
In Section 3.2 we looked at the energy cost (fitness cost) of documented escape mutations and where these costs fall in the spectrum of possible mutations. Three of the single mutations, K2471R, Q2467K, and R2937S, fall in the 36 th , 74 th and 96 th percentiles, respectively. Two of the double mutations, R2937G/I2940T and Q2467K/K2471R fall in the 33 rd and 61 st percentiles, respectively.
The relatively high energy (fitness) costs of these mutations can be rationalized by the fact that they are almost always observed in concert with compensatory mutations that place them far lower on the energy (fitness) cost spectrum. The details of those compensatory mutations follow. K2471R (36 th percentile) and Q2467K (74 th percentile) are typically observed as the double mutant, Q2467K/K2471R (61 st percentile). Furthermore, they are almost always seen in connection with another mutation H2453Y which is compensatory and mediates further immune escape [15] . H2453Y is an escape mutation in a nearby epitope presented by the same HLA We observe that the Q2467K/K2471R double mutant may represent a temporary "metastable" escape, since K2471R was observed to revert back to wild type after Q2467K was replaced by the Q2467L polymorphism. This alternative escape mutation has been reported to be less effective at mediating CTL escape, but is of much higher fitness (lower energy), falling in the 4 th percentile of the energy spectrum [15] . R2937S (96 th percentile) is very rare and is always observed to be accompanied by E2875K and P2881Q [10] . This E2875K/P2881Q/R2937S triple mutant falls in the 4 th percentile of all triple mutants and has an energy cost ∆E = 13.26. R2937G/I2940T (33 rd percentile) is also very rare and always observed with E2875K and P2881Q [10] .
IV. LONGITUDINAL CLONAL SEQUENCING STUDY
In Section 3.4 we analyzed longitudinal sequencing data of HCV progression in Patient M003 and the two children to whom she gave birth during the study and vertically transmitted HCV -Patients C003 and D003 -as reported in Ref. [15] . For concision, we considered in the main text only the average energy assigned by our model to the strains at each time point,Ē, in our predictions of the fitness of the viral ensemble over the course of the study. Here we present a more detailed analysis of the clonal sequencing data for M003 (and her children C003 and D003), for whom multiple sequences are available for each time point. HLA molecules, and position 2510 which is associated with an A*31 associated polymorphism (S2510N) [16] . As our reference sequence for this analysis we adopt the consensus sequence at the first time point of the study at 0.0 months.
M003 presented with acute HCV during her pregnancy with C003 at 0.0 months. Consistent with a suppressed immune system due to maternofatel immune tolerance, our model assigns high fitness (low energy) to the sequences retrieved at this time and at the time of delivery (1.3 months).
The sequences reveal scattered mutations within epitopes, but all are transient and do not appear to be correlated with host immune pressure.
After delivery of C003 at 7.2 months our model predicts a sharp decrease in fitness (increase in energy) in all sequences reported in M003, that appears to be correlated with an increase in host immune pressure due to disappearance of the maternofetal immune tolerance mechanism after delivery of the infant. In particular, the sequence ensemble contains four immune related polymorphisms: H2453Y, Q2467X, K2471R, and S2510N. The H2453Y mutation appears in epitope B*15-LLRHHNLVY 2450−2458 and is known to abrogate T-cell recognition [15] . The mutations Q2467X and K2471R appear in epitope B*15-SQRQKKVTF 2466−2474 . Although the specific information on all polymorphisms present is not available, Q2476L is reported to decrease T-cell recognition and Q2467K/K2471R to abolish it [15] . Our model predicts the energy cost of Q2467K (∆E = 9.0) to be more than three times that of Q2467L (∆E = 2.8). The elimination of Q2467L in favor of Q2467K by month 10.7 is consistent with a scenario of mounting immune pressure on this epitope, and the fixation of a higher fitness cost escape mutation that more effectively abrogates T-cell recognition. The A*31 associated polymorphism S2510N also becomes fixed in M003 after delivery, consistent with her HLA haplotype.
As M003 enters a second pregnancy with D003 at month 8.3, our model again predicts an increase in the fitness of the viral ensemble (decrease in energy) consistent with suppression of specific HCV host immune pressure by the maternofetal immune tolerance mechanism. In addition to an increase in fitness (decrease in energy) of most sequences, by month 16.8, K2471R has reverted to wild type, and Q2467K/H to Q2467L in all but one sequence, consistent with a decrease in host immune pressure mediating the reversion of high fitness cost escape mutations. These reversions Our model predicts that Q2467T/K2451R (∆E = 18.2) is less fit than Q2467K/K2451R (∆E = 16.3); however we see a increase in the fitness of the strains with Q2467T/K2451R indicating that compensatory mutations arose to make it more fit.
None of the sequences vertically transmitted to either child C003 and D003 show significant differences from the maternal sequences at (or near) the time of birth. Sequences within C003 25 weeks after birth (at 7.2 months) contain none of the escape mutations that arose within in the mother after delivery, consistent with transmission of a fit HCV strain from the immunosuppressed mother "outrunning" the nascent immune system of the newborn [15] . Sequences within D003 12 weeks after birth (at 20.1 months) contain the S2510N polymorphism and H2453Y and Q2467L polymorphisms within the HLA-B*15 associated epitopes LLRHHNLVY 2450−2458 and SQRQKKVTF 2466−2474 present in the mother before delivery, and constitute a slightly more fit population (E = 52.2) of viral strains than those of the mother at time of delivery. D003 inherited the HLA-B*1501 class I molecule from the mother, and that reversion of the polymorphisms within these unfit strains is not observed is consistent with continued immune pressure at these epitopes by the child's immune system. 
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The number of components corresponds to the number of epitopes in the immunogen candidate, the population coverage is the fraction of the target population of the the top 66 haplotypes of
North Americans who respond to at least one epitope in the immunogen candidate, and ∆ E is the weighted averaged impact of the immunogen upon the fitness of the viral ensemble within the target population as defined in Section 3.6. The particular epitopes in the immunogen candidate reported in the last column correspond to the indices in the "Index" column in Table S3. 2450  2458  2466  2474  2510  2578  2587  2594  2602  2727  2735  3003 3011 
